At The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), our vision is to create a cancer-free world, one person, one discovery at a time. This underlies everything we do in working to eradicate cancer through research that translates to innovative and highly targeted patient care.
The OSUCCC – James is the only cancer program in the United States that features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic health center and a freestanding cancer hospital on the campus of one of the nation’s largest public universities.
The OSUCCC – James has been designated as an NCI Comprehensive Cancer Center since 1976. Also, it is one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer agents provided by the NCI. The Comprehensive Cancer Center contains five highly interactive and collaborative cancer research programs: Cancer Control; Leukemia and Hematologic Malignancies; Cancer Biology; Molecular Carcinogenesis and Chemoprevention; and Translational Therapeutics. More than 420 scientists from 12 of the 15 colleges at Ohio State are funded members of one of these research programs. Altogether, Ohio State’s cancer program comprises some 1,700 researchers.
As the cancer program’s adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report for 25 years and has achieved Magnet® recognition, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors, more than 1.1 million square feet and 356 inpatient beds, The James is the third-largest cancer hospital in the nation – a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.
Through this integration, the OSUCCC – James is a global leader in such emerging disciplines as cellular therapy and immuno-oncology. In 2017, the OSUCCC – James was among the first hospitals in the United States to offer the first cellular therapy for blood cancers, known as CAR T-cell therapy, and is playing a major role in the continuing development of this and other cellular therapies.
To increase critically needed cancer research funding, a three-day cycling fundraising event and movement called Pelotonia was created in 2008 to raise money for cancer research at the OSUCCC – James. To date, this inspirational grassroots event has raised more than $283 million. In 2019, with funds raised by Pelotonia, the OSUCCC – James launched the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body’s immune system to fight cancer at all levels.
To learn more, visit https://cancer.osu.edu/.